AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) declared that the U.S. Food and Drug Administration (FDA) has acknowledged Fast Track finding to ferumoxytol for its utilization as a characteristic businessperson for Vascular-Enhanced Magnetic Resonance Imaging (VE-MRI) to meliorate the categorization of marginal arterial disease in patients with famous or suspected habitual kidney disease (CKD).

Tags: imaging, magnetic resonance imaging, MRI, vascular